Abattis Bioceuticals

Abattis Bioceuticals Corp (OTCQX: ATTBF) (CSE: ATT) is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions by supplying and partnering with companies to employ its vertical cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The company also has an extensive pipeline of high-quality products and Intellectual Property for the rapidly expanding botanical drug market. We follow strict Standard Operating Protocols and adhere to the Law's of Canada and Foreign Jurisdictions.

Listing Details

Telephone

(604) 336-0881

Website

www.abattis.com

Stock Quote

Invest In MJ Charts:

News

Latest News About Abattis Bioceuticals (OTCQB: ATTBF) (CSE: ATT)

ABATTIS ANNOUNCES RENEWAL OF HEALTH CANADA LICENCE

November 7, 2016

Abattis Bioceuticals Corp. | Vancouver, B.C.

Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQB: ATTBF) (CSE: ATT), announces the renewal of the Health Canada Licence for the Northern Vine Canada Inc. testing lab.

Health Canada has confirmed the renewal of the Langley, BC facility’s controlled substances testing licence. The Company has fulfilled Health Canada’s rigorous specifications, and successfully completed all thorough inspections. Accordingly, the lab has received its controlled substances licence renewal for the 2017 year.

The Company has worked hard to meet the requirements within Health Canada’s strictly regulated licensing environment. It is a testament to the professionalism of the team that has maintained the high standards of safety, quality and security in accordance with Health Canada’s regulations governing controlled substances testing facilities. This is an annual requirement and a big step toward Abattis entering the revenue stage for its shareholders.

Rating